Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
Advagene Biopharma
Welcome,
Profile
Billing
Logout
Products
Diseases
Products
Trials
News
|
|||||||||
AD17002
/
Advagene Biopharma
Phase classification, Trial completion date, Trial primary completion date:
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
(clinicaltrials.gov) - Dec 22, 2023
P1/2
, N=30, Completed,
Sponsor: Advagene Biopharma Co. Ltd.
Phase classification: P2a --> P1/2 | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Oct 2023
|||
|||||||
AD17002
/
Advagene Biopharma
Trial completion date, Trial primary completion date:
Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19
(clinicaltrials.gov) - Dec 19, 2023
P2/3
, N=180, Recruiting,
Sponsor: Advagene Biopharma Co. Ltd.
Phase classification: P2a --> P1/2 | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Oct 2023 Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Oct 2024
||
||||||||
AD17002
/
Advagene Biopharma
New P2 trial:
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
(clinicaltrials.gov) - Aug 14, 2023
P2
, N=40, Not yet recruiting,
Sponsor: Advagene Biopharma Co. Ltd.
||||
||||||
AD17002
/
Advagene Biopharma
Enrollment open, Trial completion date, Trial primary completion date:
Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19
(clinicaltrials.gov) - Jul 27, 2023
P2/3
, N=180, Recruiting,
Sponsor: Advagene Biopharma Co. Ltd.
Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Oct 2024 Not yet recruiting --> Recruiting | Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
||
||||||||
AD17002
/
Advagene Biopharma
Trial completion, Trial primary completion date:
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
(clinicaltrials.gov) - Jul 27, 2023
P2a
, N=30, Completed,
Sponsor: Advagene Biopharma Co. Ltd.
Not yet recruiting --> Recruiting | Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Recruiting --> Completed | Trial primary completion date: Oct 2022 --> May 2023
||||||||
||
AD17002
/
Advagene Biopharma
New P2/3 trial:
Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19
(clinicaltrials.gov) - Sep 15, 2022
P2/3
, N=180, Not yet recruiting,
Sponsor: Advagene Biopharma Co. Ltd.
|
|||||||||
AD17002
/
Advagene Biopharma
Trial completion date, Trial initiation date, Trial primary completion date:
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
(clinicaltrials.gov) - Aug 9, 2022
P2a
, N=30, Recruiting,
Sponsor: Advagene Biopharma Co. Ltd.
Recruiting --> Completed | Trial primary completion date: Oct 2022 --> May 2023 Trial completion date: Apr 2022 --> Feb 2023 | Initiation date: Dec 2021 --> Mar 2022 | Trial primary completion date: Apr 2022 --> Oct 2022
||
||||||||
AD17002
/
Advagene Biopharma
Enrollment open:
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
(clinicaltrials.gov) - Dec 6, 2021
P2a
, N=30, Recruiting,
Sponsor: Advagene Biopharma Co. Ltd.
Trial completion date: Apr 2022 --> Feb 2023 | Initiation date: Dec 2021 --> Mar 2022 | Trial primary completion date: Apr 2022 --> Oct 2022 Not yet recruiting --> Recruiting
||
||||||||
AD17002
/
Advagene Biopharma
New P2a trial:
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
(clinicaltrials.gov) - Oct 5, 2021
P2a
, N=30, Not yet recruiting,
Sponsor: Advagene Biopharma Co. Ltd.
||
||||||||
AD17002
/
Advagene Biopharma
Trial completion:
Tolerability and Potential Efficacy of LTh(αΚ) in Subjects With Allergic Rhinitis
(clinicaltrials.gov) - Sep 17, 2021
P1/2
, N=48, Completed,
Sponsor: Advagene Biopharma Co. Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
|
|||||||||
AD17002
/
Advagene Biopharma
Enrollment closed:
Tolerability and Potential Efficacy of LTh(αΚ) in Subjects With Allergic Rhinitis
(clinicaltrials.gov) - Nov 12, 2020
P1/2
, N=48, Active, not recruiting,
Sponsor: Advagene Biopharma Co. Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
|
|||||||||
AD17002
/
Advagene Biopharma
New P1/2 trial:
Tolerability and Potential Efficacy of LTh(αΚ) in Subjects With Allergic Rhinitis
(clinicaltrials.gov) - Sep 13, 2019
P1/2
, N=48, Recruiting,
Sponsor: Advagene Biopharma Co. Ltd.